A new decade awaits sticky platelet syndrome: where are we now, how do we manage and what are the complications?
Expert Rev Hematol. 2022 Jan 15. doi: 10.1080/17474086.2022.2030217. Online ahead of print.ABSTRACTINTRODUCTION: Sticky platelet syndrome is a less known platelet function disorder with a familiar occurrence and likely genetic background. Clinically, it is characterized by an increased risk of venous and arterial thromboembolic events and obstetric placenta-mediated complications. The increased aggregation after low-dose ADP and/or epinephrine is its distinctive laboratory feature. Though described for almost 40 years, several issues regarding its etiology, involved pathomechanisms, genetic background, optimal diagnostic a...
Source: Expert Review of Hematology - January 17, 2022 Category: Hematology Authors: Jan Stasko Pavol Holly Peter Kubisz Source Type: research

COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis
CONCLUSION: our analysis show that ITP secondary to COVID-19 infection is slightly more prevalent among males (54.8%). Elderly patients were more vulnerable to have the disease as most of the cases were older than 50 years with a median age of 63 years. Most cases developed ITP within 2-3 weeks after COVID-19 infection and recovered in less than one week from ITP.PMID:35025706 | DOI:10.1080/17474086.2022.2029699 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - January 13, 2022 Category: Hematology Authors: Mohammed Ghannam Alharbi Source Type: research

Autologous hematopoietic stem cell grafts - moving away from a one-size-fits-all approach
Expert Rev Hematol. 2022 Jan 6:1-4. doi: 10.1080/17474086.2022.2022470. Online ahead of print.NO ABSTRACTPMID:34949139 | DOI:10.1080/17474086.2022.2022470 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - December 24, 2021 Category: Hematology Authors: Guro Kristin Melve Miriam Sandnes H åkon Reikvam Source Type: research

Autologous hematopoietic stem cell grafts - moving away from a one-size-fits-all approach
Expert Rev Hematol. 2021 Dec 23. doi: 10.1080/17474086.2022.2022470. Online ahead of print.NO ABSTRACTPMID:34949139 | DOI:10.1080/17474086.2022.2022470 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - December 24, 2021 Category: Hematology Authors: Guro Kristin Melve Miriam Sandnes H åkon Reikvam Source Type: research

A critical evaluation of crizanlizumab for the treatment of sickle cell disease
Expert Rev Hematol. 2021 Dec 23. doi: 10.1080/17474086.2022.2023007. Online ahead of print.ABSTRACTINTRODUCTION: P-selectin is a key adhesion molecule in the pathogenesis of sickle cell disease, including acute painful event(s). Many of the mediators activated in prototypical pain crisis are also involved in other complications seen in this population. Crizanlizumab is a monoclonal antibody approved in the US in 2019 for patients of all genotypes of sickle cell disease. By blocking P-selectin, it effectively prevents acute painful event(s) and has a manageable safety profile.AREAS COVERED: In this review, we provide an ove...
Source: Expert Review of Hematology - December 23, 2021 Category: Hematology Authors: Nabin Raj Karki Katherine Saunders Abdullah Kutlar Source Type: research

The development of a home-based therapeutic platform for multiple myeloma
CONCLUSION: We have enabled large numbers of patients to receive complex therapies in their own home and the COVID-19 pandemic has increased the pace of the roll out without any compromise in safety. We anticipate that the next raft of immunotherapies will be able to transition into the @Home treatment setting in the coming years.PMID:34936527 | DOI:10.1080/17474086.2021.2022471 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - December 22, 2021 Category: Hematology Authors: Hayley Beer David Routledge Trish Joyce Emma-Jane Furphy Nella Combe David Ritchie Amit Khot Seok Ming Lim Michael Montalto Simon J Harrison Source Type: research

A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma
Expert Rev Hematol. 2021 Dec 14. doi: 10.1080/17474086.2022.2018297. Online ahead of print.ABSTRACTINTRODUCTION: The modern treatment of patients with primary central nervous system lymphoma (PCNSL) consists of two phases: induction, currently represented by a high-dose-methotrexate-based polychemotherapy, and consolidation. The optimal consolidation therapy has not been defined yet, but several strategies, such as whole-brain radiotherapy (WBRT), high-dose chemotherapy supported by autologous stem cell transplantation (HDC/ASCT) or non-myeloablative chemotherapy, have been addressed in important randomized trials.AREAS CO...
Source: Expert Review of Hematology - December 14, 2021 Category: Hematology Authors: Sara Steffanoni Teresa Calimeri Nicoletta Anzalone Sara Mastaglio Massimo Bernardi Andr és Jm Ferreri Source Type: research

Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients
Expert Rev Hematol. 2021 Dec 11. doi: 10.1080/17474086.2022.2018296. Online ahead of print.ABSTRACTINTRODUCTION: In chronic myeloid leukemia (CML) patients who have reached a deep and sustained reduction of residual disease can attempt a discontinuation. The "treatment-free remission" (TFR) has become a real long-term endpoint for 30-40% of chronic phase patients.AREAS COVERED: In this review, we focus our attention on possible prognostic features who can predict the success of tyrosine kinase inhibitors discontinuation and how we can assess the minimal residual disease (MRD) during the TFR phase. Broad research ...
Source: Expert Review of Hematology - December 13, 2021 Category: Hematology Authors: Massimo Breccia Emilia Scalzulli Sara Pepe Gioia Colafigli Maria Laura Bisegna Marcello Capriata Maurizio Martelli Source Type: research

Efficacy and safety of thrombopoietin receptor agonists in the treatment of thrombocytopenia after hematopoietic stem cell transplantation: a meta-analysis and systematic review
Expert Rev Hematol. 2021 Dec 1:1-8. doi: 10.1080/17474086.2021.2009337. Online ahead of print.ABSTRACTThrombocytopenia is a tough complication after hematopoietic stem cell transplantation (HSCT) with elusive pathogenesis and lack of well-established therapies. Thrombopoietin receptor agonists (TPO-RAs) have been used for thrombocytopenia post HSCT in recent years, but the outcomes remain debatable. We conducted this meta-analysis and systematic-review to evaluate the efficacy and safety of TPO-RAs for platelet recovery after HSCT. We searched PubMed, EMBASE, and Cochrane databases for studies on the application of TPO-RAs...
Source: Expert Review of Hematology - November 30, 2021 Category: Hematology Authors: Yifang Yao Yaqiong Tang JiaQian Qi Xueqian Li Rui Zhang Xiaoyan Xu Tingting Pan Yue Han Source Type: research

Emerging roles of microRNAs in acute lymphoblastic leukemia and their clinical prospects
Expert Rev Hematol. 2021 Nov 26:1-6. doi: 10.1080/17474086.2021.2007763. Online ahead of print.ABSTRACTINTRODUCTION: Targeted therapy with microRNAs (miRNAs) has been a significant challenge in recent years. Studying the role and mechanism through which miRNAs regulate various cancer processes is very critical in cancer treatment, including acute lymphoblastic leukemia (ALL).AREAS COVERED: This review summarizes the diverse roles of miRNAs in ALL and provides new perspectives in miRNA-based therapeutic strategies.EXPERT OPINION: MiRNAs belong to a kind of endogenous non-coding small RNA with the length of 19 ~ 25 nucleotid...
Source: Expert Review of Hematology - November 17, 2021 Category: Hematology Authors: Wei Deng Ming Pan Shengdong Zhu Rong Chao Li Wang Source Type: research

Exercise and anemia in cancer patients: could make the difference?
Expert Rev Hematol. 2021 Nov 16. doi: 10.1080/17474086.2021.2007764. Online ahead of print.ABSTRACTINTRODUCTION: Anemia is one of the most common hematological manifestations occurring in cancer patients, related to a poorer prognosis. Among supportive care in cancer, exercise is emerging as a crucial tool demonstrating to reduce mortality risk, as well as to counteract several diseases and treatment-related adverse events. Nevertheless, the effect of exercise on anemia in cancer is still a relatively unexplored area.AREA COVERED: Six studies investigated the impact of exercise on anemia trajectory in cancer patients, with...
Source: Expert Review of Hematology - November 17, 2021 Category: Hematology Authors: Alice Avancini Lorenzo Belluomini Daniela Tregnago Ilaria Trestini Michele Milella Massimo Lanza Sara Pilotto Source Type: research

Emerging roles of microRNAs in acute lymphoblastic leukemia and their clinical prospects
Expert Rev Hematol. 2021 Nov 26:1-6. doi: 10.1080/17474086.2021.2007763. Online ahead of print.ABSTRACTINTRODUCTION: Targeted therapy with microRNAs (miRNAs) has been a significant challenge in recent years. Studying the role and mechanism through which miRNAs regulate various cancer processes is very critical in cancer treatment, including acute lymphoblastic leukemia (ALL).AREAS COVERED: This review summarizes the diverse roles of miRNAs in ALL and provides new perspectives in miRNA-based therapeutic strategies.EXPERT OPINION: MiRNAs belong to a kind of endogenous non-coding small RNA with the length of 19 ~ 25 nucleotid...
Source: Expert Review of Hematology - November 17, 2021 Category: Hematology Authors: Wei Deng Ming Pan Shengdong Zhu Rong Chao Li Wang Source Type: research

Exercise and anemia in cancer patients: could make the difference?
Expert Rev Hematol. 2021 Nov 16. doi: 10.1080/17474086.2021.2007764. Online ahead of print.ABSTRACTINTRODUCTION: Anemia is one of the most common hematological manifestations occurring in cancer patients, related to a poorer prognosis. Among supportive care in cancer, exercise is emerging as a crucial tool demonstrating to reduce mortality risk, as well as to counteract several diseases and treatment-related adverse events. Nevertheless, the effect of exercise on anemia in cancer is still a relatively unexplored area.AREA COVERED: Six studies investigated the impact of exercise on anemia trajectory in cancer patients, with...
Source: Expert Review of Hematology - November 17, 2021 Category: Hematology Authors: Alice Avancini Lorenzo Belluomini Daniela Tregnago Ilaria Trestini Michele Milella Massimo Lanza Sara Pilotto Source Type: research

Emerging roles of microRNAs in acute lymphoblastic leukemia and their clinical prospects
Expert Rev Hematol. 2021 Nov 26:1-6. doi: 10.1080/17474086.2021.2007763. Online ahead of print.ABSTRACTINTRODUCTION: Targeted therapy with microRNAs (miRNAs) has been a significant challenge in recent years. Studying the role and mechanism through which miRNAs regulate various cancer processes is very critical in cancer treatment, including acute lymphoblastic leukemia (ALL).AREAS COVERED: This review summarizes the diverse roles of miRNAs in ALL and provides new perspectives in miRNA-based therapeutic strategies.EXPERT OPINION: MiRNAs belong to a kind of endogenous non-coding small RNA with the length of 19 ~ 25 nucleotid...
Source: Expert Review of Hematology - November 17, 2021 Category: Hematology Authors: Wei Deng Ming Pan Shengdong Zhu Rong Chao Li Wang Source Type: research

Exercise and anemia in cancer patients: could make the difference?
Expert Rev Hematol. 2021 Nov 16. doi: 10.1080/17474086.2021.2007764. Online ahead of print.ABSTRACTINTRODUCTION: Anemia is one of the most common hematological manifestations occurring in cancer patients, related to a poorer prognosis. Among supportive care in cancer, exercise is emerging as a crucial tool demonstrating to reduce mortality risk, as well as to counteract several diseases and treatment-related adverse events. Nevertheless, the effect of exercise on anemia in cancer is still a relatively unexplored area.AREA COVERED: Six studies investigated the impact of exercise on anemia trajectory in cancer patients, with...
Source: Expert Review of Hematology - November 17, 2021 Category: Hematology Authors: Alice Avancini Lorenzo Belluomini Daniela Tregnago Ilaria Trestini Michele Milella Massimo Lanza Sara Pilotto Source Type: research

Emerging roles of microRNAs in acute lymphoblastic leukemia and their clinical prospects
Expert Rev Hematol. 2021 Nov 26:1-6. doi: 10.1080/17474086.2021.2007763. Online ahead of print.ABSTRACTINTRODUCTION: Targeted therapy with microRNAs (miRNAs) has been a significant challenge in recent years. Studying the role and mechanism through which miRNAs regulate various cancer processes is very critical in cancer treatment, including acute lymphoblastic leukemia (ALL).AREAS COVERED: This review summarizes the diverse roles of miRNAs in ALL and provides new perspectives in miRNA-based therapeutic strategies.EXPERT OPINION: MiRNAs belong to a kind of endogenous non-coding small RNA with the length of 19 ~ 25 nucleotid...
Source: Expert Review of Hematology - November 17, 2021 Category: Hematology Authors: Wei Deng Ming Pan Shengdong Zhu Rong Chao Li Wang Source Type: research

Exercise and anemia in cancer patients: could make the difference?
Expert Rev Hematol. 2021 Nov 16. doi: 10.1080/17474086.2021.2007764. Online ahead of print.ABSTRACTINTRODUCTION: Anemia is one of the most common hematological manifestations occurring in cancer patients, related to a poorer prognosis. Among supportive care in cancer, exercise is emerging as a crucial tool demonstrating to reduce mortality risk, as well as to counteract several diseases and treatment-related adverse events. Nevertheless, the effect of exercise on anemia in cancer is still a relatively unexplored area.AREA COVERED: Six studies investigated the impact of exercise on anemia trajectory in cancer patients, with...
Source: Expert Review of Hematology - November 17, 2021 Category: Hematology Authors: Alice Avancini Lorenzo Belluomini Daniela Tregnago Ilaria Trestini Michele Milella Massimo Lanza Sara Pilotto Source Type: research

Emerging roles of microRNAs in acute lymphoblastic leukemia and the clinical prospects
Expert Rev Hematol. 2021 Nov 16. doi: 10.1080/17474086.2021.2007763. Online ahead of print.ABSTRACTTargeted therapy with microRNAs (miRNAs) has been a significant challenge in recent years. Studying the role and mechanism through which miRNAs regulate various cancer processes is very critical in cancer treatment, including acute lymphoblastic leukemia (ALL).Areas covered: This review summarizes the diverse roles of miRNAs in ALL and provides new perspectives in miRNA-based therapeutic strategies.Expert opinion: MiRNAs belong to a kind of endogenous non-coding small RNAs with the length of 19 ~ 25 nucleotides. They inhibit ...
Source: Expert Review of Hematology - November 17, 2021 Category: Hematology Authors: Wei Deng Ming Pan Shengdong Zhu Rong Chao Li Wang Source Type: research

Exercise and anemia in cancer patients: could make the difference?
Expert Rev Hematol. 2021 Nov 16. doi: 10.1080/17474086.2021.2007764. Online ahead of print.ABSTRACTINTRODUCTION: Anemia is one of the most common hematological manifestations occurring in cancer patients, related to a poorer prognosis. Among supportive care in cancer, exercise is emerging as a crucial tool demonstrating to reduce mortality risk, as well as to counteract several diseases and treatment-related adverse events. Nevertheless, the effect of exercise on anemia in cancer is still a relatively unexplored area.AREA COVERED: Six studies investigated the impact of exercise on anemia trajectory in cancer patients, with...
Source: Expert Review of Hematology - November 17, 2021 Category: Hematology Authors: Alice Avancini Lorenzo Belluomini Daniela Tregnago Ilaria Trestini Michele Milella Massimo Lanza Sara Pilotto Source Type: research

Emerging roles of microRNAs in acute lymphoblastic leukemia and the clinical prospects
Expert Rev Hematol. 2021 Nov 16. doi: 10.1080/17474086.2021.2007763. Online ahead of print.ABSTRACTTargeted therapy with microRNAs (miRNAs) has been a significant challenge in recent years. Studying the role and mechanism through which miRNAs regulate various cancer processes is very critical in cancer treatment, including acute lymphoblastic leukemia (ALL).Areas covered: This review summarizes the diverse roles of miRNAs in ALL and provides new perspectives in miRNA-based therapeutic strategies.Expert opinion: MiRNAs belong to a kind of endogenous non-coding small RNAs with the length of 19 ~ 25 nucleotides. They inhibit ...
Source: Expert Review of Hematology - November 17, 2021 Category: Hematology Authors: Wei Deng Ming Pan Shengdong Zhu Rong Chao Li Wang Source Type: research

Exercise and anemia in cancer patients: could make the difference?
Expert Rev Hematol. 2021 Nov 16. doi: 10.1080/17474086.2021.2007764. Online ahead of print.ABSTRACTINTRODUCTION: Anemia is one of the most common hematological manifestations occurring in cancer patients, related to a poorer prognosis. Among supportive care in cancer, exercise is emerging as a crucial tool demonstrating to reduce mortality risk, as well as to counteract several diseases and treatment-related adverse events. Nevertheless, the effect of exercise on anemia in cancer is still a relatively unexplored area.AREA COVERED: Six studies investigated the impact of exercise on anemia trajectory in cancer patients, with...
Source: Expert Review of Hematology - November 17, 2021 Category: Hematology Authors: Alice Avancini Lorenzo Belluomini Daniela Tregnago Ilaria Trestini Michele Milella Massimo Lanza Sara Pilotto Source Type: research